Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OPKO Health Collaborates with Entera Bio for Metabolic Disorder Treatment
Collaborations & Alliances

OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1

Aims to advance once-daily tablet treatment for patients with obesity, metabolic, and fibrotic disorders.

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic, and fibrotic disorders. 

The program combines OPKO’s oxyntomodulin analog (OPK-88006) and Entera’s N-Tab technology. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year.

Oxyntomodulin is a naturally occurring GLP-1/glucagon dual agonist peptide hormone found in the small intestine that acts to suppress appetite, induce weight loss, and has additional cardioprotective and anti-fibrotic attributes.

OPK-88006 is a GLP-1/glucagon dual agonist peptide that has been modified to maintain its long-acting profile while increasing its potential potency. Currently, there are no approved dual GLP-1/glucagon agonists available.

Under the terms of the agreement, OPKO and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program’s development costs, respectively. 

In connection with the execution of the agreement, OPKO purchased 3,685,226 ordinary shares of Entera for a purchase price equal to $2.17 per share. Entera has agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program. 

After the Phase 1 stage is complete, Entera can continue to fund its 40% share to maintain its pro-rata ownership interest in the program. Should Entera opt out, Entera will retain a 15% ownership interest in the Oral OXM program, while OPKO will retain 85% and be responsible for ongoing development activities and funding of the program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters